16 September 2026 editorial review · Trial
Genetically informed screening: MGB Biobank: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: New biobank genetic-recall observational screening, target 150 ages18–79; selected polygenic risk, not a public population screening service.
Registry: NCT07802496; NOT_YET_RECRUITING; updated 2026-09-08; enrollment 150 (ESTIMATED); results not posted.
Endpoint comparison: Comparisons between high genetic risk vs. the rest of the cohort (12 months).
Sources for this record: Genetically Informed Screening for Early-Stage Type 1 Diabetes (NCT07802496) (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.